Cheney's doctors said the procedure began with an electrophysiology study (EPS) to determine the vice president's risk of developing arrhythmia, or irregular heartbeat.
The Bethpage, New York-based company underperformed the Street's expectations though, with 37 cents EPS that was short of the 41-cent consensus estimate.